论文部分内容阅读
目的分析不同的CYP2C9和VKORC1分型患者胺碘酮对华法林的抗凝作用的影响。方法纳入从2010年1月至2012年11月某三甲医院应用华法林的入院患者,收集患者一般信息、合并用药及其他临床相关数据,检测患者VKORCl和CYP2C9基因型;比较使用或未使用胺碘酮治疗患者抗凝稳定期INR值及华法林用量,纳入基因分型进行华法林/胺碘酮相互作用的亚组分析。结果未发现胺碘酮应用患者华法林稳定期用量和INR值的统计学差义,基因型亚组差异无统计学意义。结论院内短期合并使用胺碘酮患者对华法林稳定剂量和INR值未见显著影响。
Objective To analyze the effect of amiodarone on warfarin anticoagulation in patients with different CYP2C9 and VKORC1 types. Methods Patients admitted to a top-third hospital from January 2010 to November 2012 with warfarin were enrolled. General information, combined medication and other clinically relevant data were collected and the genotypes of patients with VKORCl and CYP2C9 were tested. The patients with and without amine Stable anticoagulation INR values and warfarin levels were included in patients treated with idiopathic iodine and subtype analyzes of warfarin / amiodarone interaction were included in the genotyping. The results did not find the application of amiodarone in patients with stable warfarin dosage and INR value of the statistical significance of genotypic subgroup differences were not statistically significant. Conclusions There was no significant effect of short-term amiodarone on warfarin dose and INR.